A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease
Nour Sabiha Naji(Johns Hopkins University), Theodoros Karantanos(The University of Texas MD Anderson Cancer Center), Ivana Gojo(Johns Hopkins University), Theodora Chatzilygeroudi(Johns Hopkins University), Suman Paul(Johns Hopkins University), Tushar D. Nichakawade(Howard Hughes Medical Institute), Li Luo(City Of Hope National Medical Center), Bogdan Paun(Sidney Kimmel Comprehensive Cancer Center), Xinghan Zeng(Johns Hopkins University), Bum Seok Lee(Johns Hopkins University), Melanie Klausner(Johns Hopkins University), Yashvi Hemani, Linda M. S. Resar(Johns Hopkins University), J. David Peske(Johns Hopkins University), Yuju An(Johns Hopkins University), Yanyan Wang, Taha Soueidatt Ahmedna(Johns Hopkins University), Gabriel Ghiaur(Johns Hopkins University), Amy E. DeZern(Sidney Kimmel Comprehensive Cancer Center), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Brandy Perkins(Johns Hopkins University), Styliani Karanika(Johns Hopkins University), Zanshé Thompson(Johns Hopkins University), Evangeline Watson(Howard Hughes Medical Institute), Mark J. Levis(Johns Hopkins University), Teodora Supeanu(Johns Hopkins University)
Cited by 0
Related Papers
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
|Oncogene|2013|879
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
|Blood|2015|299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
|Haematologica|2016|187